Novocure (NVCR) CEO Asaf Danziger Sold $32.7 million of Shares

- By insider

CEO of Novocure (30-Year Financial, Insider Trades) Asaf Danziger (insider trades) sold 207,910 shares of NVCR on 12/18/2020 at an average price of $157.39 a share. The total sale was $32.7 million.

• Warning! GuruFocus has detected 6 Warning Signs with COUP. Click here to check it out.

• NVCR 15-Year Financial Data

• The intrinsic value of NVCR

• Peter Lynch Chart of NVCR

NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. NovoCure Ltd has a market cap of $17.41 billion; its shares were traded at around $171.000000 with a P/E ratio of 900.00 and P/S ratio of 40.35.

CEO Recent Trades:

• CEO Asaf Danziger sold 207,910 shares of NVCR stock on 12/18/2020 at the average price of $157.39. The price of the stock has increased by 8.65% since.

Directors and Officers Recent Trades:

• Chief Medical Officer Ely Benaim sold 2,484 shares of NVCR stock on 12/21/2020 at the average price of $156.71. The price of the stock has increased by 9.12% since.

• Director Jeryl L Hilleman sold 2,500 shares of NVCR stock on 12/18/2020 at the average price of $166.4. The price of the stock has increased by 2.76% since.

For the complete insider trading history of NVCR, click here

.This article first appeared on GuruFocus.